Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome

Documenti analoghi

• Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
  di: Scott A. Coon, et al.
  Pubblicazione: (2025)
• The cardio‐metabolic protein profile is associated with development of type 2 diabetes at long term follow‐up after gestational diabetes mellitus: Results from the OGFUS study
  di: Simone J. Hallig, et al.
  Pubblicazione: (2025)
• Anabolic androgenic steroid use and risk of diabetes mellitus in males
  di: Frederik Viggo Lautrup Esmann, et al.
  Pubblicazione: (2025)
• Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19: Up to 40 months’ follow‐up
  di: Shiv Mehrotra‐Varma, et al.
  Pubblicazione: (2024)
• Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
  di: Jonathan Brix Winther, et al.
  Pubblicazione: (2024)